A Research Study to Evaluate the Efficacy and Safety of SGC001 in Patients With Anterior Wall ST-Segment Elevation Myocardial Infarction

A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 210 participants.

Also called NCT07306182

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 210 participants (planned count) (from the registry)
Sponsor
Beijing Sungen Biomedical Technology Co., Ltd (from the registry)
Registry
  • NCT NCT07306182
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07306182. Randomized; quadruple masking; primary purpose treatment. Start 2026-03-09 (actual); primary completion 2027-04 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Research Study to Evaluate the Efficacy and Safety of SGC001 in Patients With Anterior Wall ST-Segment Elevation Myocardial Infarction
Condition
Acute Anterior ST-Segment Elevation Myocardial Infarction
Intervention (Drug)
SGC001 injection
Intervention (Drug)
SGC001 injection
Intervention (Drug)
Placebo
Lead sponsor
Beijing Sungen Biomedical Technology Co., Ltd (class: industry)

Record details

Record id
cardio:ct-nct07306182
Content hash
140347776ea336f3b0c49f5cb8ed249d57be220d3ab6a8047b9e6737b8c0c24d